Press Releases

SEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021 SEL-212 enrollment on track with topline data from DISSOLVE phase 3 program expected in second half of 2022 IND filing for IgA nephropathy program expected by the end of 2021 IND filing

WATERTOWN, Mass. , May 06, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to

WATERTOWN, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced three upcoming

– Methylmalonic Acidemia ( MMA) program to become wholly-owned by Selecta – – Selecta to postpone IND submission until at least the fourth quarter of 2021 – – Empty capsid (SEL-399) study remains on track – WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C.

WATERTOWN, Mass. , April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief

-   First-in-human dose-escalation study to evaluate ability of ImmTOR™  to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - -   Methylmalonic acidemia   (MMA) gene therapy program in collaboration with AskBio expected to enter the clinic in

WATERTOWN, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to

WATERTOWN, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief

- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector - - ImmTOR shown to increase hepatic vector copy numbers and transgene mRNA expression - - Replicated findings supporting ImmTOR’s ability to block the formation of

– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy – WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.